Stopping Ulcerative Colitis Progression in its Tract: Combining the Latest Evidence and Engaging Teaching Tools to Improve Patient Outcomes
CMEO Medical Meeting
Symposium Date: Sunday, June 3, 2018
On June 3, 2018, Marriott Marquis, Washington, DC
This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- ABIM (ABIM)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date: Monday, June 3, 2019
|David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Co-Director, Digestive Diseases Center
University of Chicago Medicine
|Miguel Regueiro, MD, AGAF, FACG, FACP
Chair, Department of Gastroenterology and Hepatology
Vice Chair, Digestive Disease and Surgery Institute
Professor of Medicine, Lerner College of Medicine
Managing patients with ulcerative colitis (UC) is as complex as the disease itself. As science progresses the understanding of UC, strategies for its management have also progressed. Treatment goals have now shifted from resolution of symptoms to full control of the disease (clinical remission and mucosal healing), with a final aim of halting or preventing disease progression, surgery, and disability; and restoration of quality of life.
This symposium, featuring interactive infographics and live webstream, will provide clinicians with evidence-based direction to achieve sustained remission in UC through implementation of early intervention of treat-to-target approaches as recommended by the AGA UC Care Pathway. Dr. Rubin and Dr. Regueiro will integrate interactive infographics to provide a targeted review of the MOA of biologics and explain the impact of these biologics on histological and endoscopic disease progression for learners to explore. After the symposium these infographics can serve as an educational resource for use in practice to enhance patient health literacy about UC and to facilitate shared decision-making with patients.
At the end of this CE activity, participants should be able to:
- Examine the rationale for the use of early, effective treatment in altering the progression course of ulcerative colitis (UC).
- Utilize the AGA Clinical Care Pathway to guide personalized biologic therapy to halt disease progression in UC.
- Incorporate disease activity monitoring strategies, including objective measures of disease improvement, to facilitate optimal management of UC.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Examine the rationale for the use of early, effective treatment in altering the progressive course of ulcerative colitis (UC).
- Explain the AGA UC Care Pathway to guide personalized biologic therapy to halt disease progression in UC.
- Describe disease activity monitoring strategies, including objective measures of disease improvement, to facilitate optimal management of UC.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Gastroenterologists, primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists who treat patients with ulcerative colitis.
CME Credit (Physicians):
CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.25 contact hours
Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.25 contact hours of pharmacotherapeutic contact hours.
Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTMthrough the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.25 contact hours (0.125 CEUs) Universal Activity Number:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Regueiro reports that he conducts research support for Abbvie Inc.; Janssen Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc. He receives unrestricted educational grants from Abbvie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Salix Pharmaceuticals; Shire; Takeda Pharmaceuticals U.S.A., Inc.; UCB, Inc.
Dr. Rubin reports that he receives grants from AbbVie Inc.; Genentech, Inc./Roche; Janssen Pharmaceuticals, Inc.’ Prometheus Laboratories Inc.; Shire; Takeda Pharmaceuticals U.S.A., Inc.; UCB, Inc. He is a consultant for AbbVie Inc.; AbGenomics; Allergan; Amgen Inc.; Celgene Corporation; Forward Pharma; Genentech, Inc./Roche; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Salix Pharmaceuticals; Samsung Bioepis; Sandoz; Shire; Takeda Pharmaceuticals U.S.A., Inc.; TARGET PharmaSolutions, Inc. He is on the Board of Trustees for the American College of Gastroenterology; is Co-Founder and CFO of Cornerstones Health, Inc. (non-profit); and is Co-Founder of GoDuRn, LLC.
Jeffrey Helfand, DO, MS (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Sharon Tordoff(planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS(877.263.7767).